Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
NEW YORK, NY, ALPHARETTA, GA and TEL AVIV, ISRAEL, Sept. 26, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Todos Medical, Ltd. (OTCQB:TOMDF), an innovative healthcare solutions company, today provided a corporate update to its stakeholders centered on the Company’s efforts to retool and focus primarily on addressing the Long COVID epidemic that is affecting over 15 million Americans, over 6% of the adult US population, according to the US Centers for Disease Control. Todos intends to deploy medical foods to aid physicians in the dietary management of Long COVID, optimize immune support with nutritional supplements targeting the 3CL protease, and precision diagnostic panels to assist in the diagnosis and monitoring of Long COVID patients. A recent report by David Cutler of Harvard University estimates the annual Long COVID cost to the US economy is $3.7 trillion.
Related news for (TOMDF)
- Todos Medical Announces Insolvency Proceedings in Israel
- Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
- Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics
- Todos Medical Begins Trading on the OTC Pink Marketplace